FIELD: medicine; dermatology.
SUBSTANCE: freeze samples from the damaged part of the skin in liquid nitrogen, crush, not supposing defrosting, from assays allocate total cellular water-soluble fibers with use of the lysing buffer containing 50 mM HEPES, pH 7.4, 5 mM CHAPS, 5 mM DTT in a current of 1 hour at +4°C, centrifugate the lyzed admixture, remove supernatant fluid and define quantity of total protein using the Bradford's technique, then define activity of caspase-3 a colorimetric method by definition of one of reaction products between caspase-3 and a peptide acetyl-asp-glu-shaft-asp p-nitroaniline (Ac-DEVD-pNA) - p-nitroaniline for what in the small cavity of a 96-cup tablet bring 85 mcl Assay buffer: 20 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT and 5 mcl cellular lysate, add 10 mcl substrate caspase-3: 20 mM Ac-DEVD-pNa in dimethyl sulfoxide in each small cavity and incubate an admixture of 90 minutes at 37°C, then measure optical density (OD) at 405 nanometers in each of the small cavities on the ELISA reader then count activity of the kaspase-3 under the formula: activity, micron of pNA/minutes/ml = (OD*d)/(t*v*ε), on mkg of total fiber, where: OD - the optical density, d - the dilution factor, t - reaction time in mines, v - assay volume in ml, ε - 10.5 mM, thus one unit of activity of enzyme is peer to splitting 1 micromole substrate Ac-DEVD-pNA for 1 minute at pH 7.4 and 25°C, on value of received size estimate condition of the apoptotic system and at normal value of this indicator - 0.5-0.6 un/mkg of the protein of apoptotic system estimate condition as stable, and at its rising more, than on 30-40% - as activated.
EFFECT: possibility objectively and precisely to define level of the main apoptotic protein in the damaged skin in the psoriasis centres, to estimate degree of expression of pathological process, sensitivity of a skin immediately in the psoriasis centres to action of exogenous damaging factors and to pick up individual skins adequate to a given condition, the therapy referred on depression of rate of apoptotic reactions and according to activity of pathological process.
1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR EVALUATING THE STATE OF CUTANEOUS APOPTIC SYSTEM IN PSORIASIS-SUFFERING PATIENTS | 2006 |
|
RU2311643C1 |
METHOD OF OBTAINING BIOPSY MATERIAL FROM ATHEROSCLEROSIS-AFFECTED VESSELS | 2008 |
|
RU2387384C1 |
METHOD FOR OBTAINING CASPASE-3 | 2022 |
|
RU2792795C1 |
DIPEPTIDYL PEPTIDASE IV INHIBITING AGENT AND PHARMACEUTICAL COMPOSITION THEREOF | 2011 |
|
RU2485952C2 |
METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
METHOD FOR DEVELOPING ALZHEIMER DISEASE CELL MODELS | 2013 |
|
RU2544957C2 |
METHOD OF ISOLATION OF HIGH-MOLECULAR PROTEIN ACTIVATION COMPLEX OF HUMAN CASPASE-2 | 2016 |
|
RU2671510C1 |
1-HYDROXYGERMATRANE USAGE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2742972C1 |
USE OF 1-(GERMATRAN-1-YL)-1-HYDROXYETHYLAMINE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2746321C1 |
COMPOSITION COMPRISING MIXTURE OF CD95-FC ISOFROMS | 2013 |
|
RU2648157C2 |
Authors
Dates
2009-01-20—Published
2006-12-21—Filed